By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Everist Genomics 

401 W. Morgan Road

Ann Arbor  Michigan  48108  U.S.A.
Phone: 734-929-9575 Fax: 866-625-8218


SEARCH JOBS
Everist Genomics is driving growth by developing innovative prognostics with potential for substantive impact on medical and financial outcomes. Our strategy centers on proprietary research and development, targeted acquisitions, and in-licensing. Everist Genomics is currently developing a range of products aimed at improving treatment outcomes in Cancer and Cancer Supportive Care, Cardiovascular Disease, Metabolic Disease (e.g. diabetes) and Neurodegenerative Diseases (e.g. Alzheimer’s and Parkinson’s disease).

Key Statistics


Email: CustomerService@EveristGenomics.com
Ownership: Private

Web Site: Everist Genomics
Employees:
Symbol: 
 



Industry
Diagnostics






Company News
Everist Genomics Awarded Admission to Johnson & Johnson (JNJ)'s Life Science Innovation Center 7/11/2012 9:50:42 AM
Everist Genomics Announces Publication of Validation Study Confirming OncoDefender-CRC Independently Predicts Recurrence Risk for Early Stage Colorectal Cancer Patients 6/5/2012 10:10:03 AM
Everist Genomics Forms JV Targeting Indian Market 5/22/2012 11:05:58 AM
Everist Genomics Develops World's First Comprehensive Companion Diagnostics and Prognostics Portfolio for Early Diagnosis and Improved Treatment of Colorectal Cancer 3/14/2012 10:31:26 AM
Everist Genomics Celebrates Origins and Future of Personalized Medicine 2/13/2012 10:20:12 AM
Smartphone Technology Meets Personalized Medicine in Everist Genomics' CardioDefender Diagnostic System 1/30/2012 9:38:06 AM
Everist Genomics Discovers Genes Responsible for Recurrence of Colorectal Cancer 12/7/2011 9:56:37 AM
Everist Genomics Announces Acquisition of Angiologix, Inc. 10/31/2011 10:52:57 AM
Everist Genomics Announces New Data on OncoDefender™- CRC Test for Predicting Recurrence Risk for Stage I and II Colorectal Cancer Patients 6/3/2011 10:19:44 AM
Everist Genomics Announces Worldwide Availability of OncoDefender(TM)-CRC 3/28/2011 6:44:03 AM
12
//-->